Psychedelics and substance use disorder treatment

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Substance use disorders (SUDs) represent a significant global health challenge.
• Classic psychedelics have garnered interest for their potential therapeutic effects on SUDs.
• Existing literature primarily focuses on alcohol use disorder (AUD).

Purpose of the Study:

• To review the current literature on classic psychedelic treatments for five substance use disorders: alcohol, tobacco, opioid, stimulant, and cannabis.
• To assess the evidence for the efficacy of psychedelics in treating these disorders.
• To explore the potential transdiagnostic effects of psychedelics across different SUDs.

Main Methods:

• Literature review of studies evaluating classic psychedelic treatments (LSD, psilocybin, ayahuasca) for SUDs.
• Analysis of clinical trials, naturalistic observational studies, and correlational survey data.
• Examination of biological and psychological mechanisms underlying psychedelic effects.

Main Results:

• Classic psychedelics show promise for alcohol use disorder, facilitating reduced drinking and abstinence.
• Preliminary clinical trials indicate potential benefits for tobacco and opioid use disorders.
• No clinical trials have been conducted for stimulant or cannabis use disorders.
• Observational data suggest potential broad transdiagnostic efficacy of psychedelics across multiple addictive drugs.

Conclusions:

• Classic psychedelics demonstrate potential therapeutic benefits for several substance use disorders.
• Biological mechanisms include amelioration of deficits in reward and emotional processing areas.
• Psychological mechanisms involve insights reinforcing motivation for sobriety and behavior change.
• Further research is essential to fully characterize the benefits and limitations of psychedelic treatments for SUDs.